Revenue Breakdown
Composition ()
No data
Revenue Streams
Guardant Health Inc (GH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology, accounting for 68.4% of total sales, equivalent to $158.69M. Other significant revenue streams include Biopharma and data and Screening. Understanding this composition is critical for investors evaluating how GH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Guardant Health Inc maintains a gross margin of 64.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -42.95%, while the net margin is -45.68%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively GH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GH competes directly with industry leaders such as ENSG and SOLV. With a market capitalization of $12.10B, it holds a significant position in the sector. When comparing efficiency, GH's gross margin of 64.63% stands against ENSG's 14.30% and SOLV's 51.40%. Such benchmarking helps identify whether Guardant Health Inc is trading at a premium or discount relative to its financial performance.
